Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Bartlett, N. L.
6981  Ergebnisse:
Personensuche X
?
1

Venetoclax combined with R‐ICE (VICER) for second line trea..:

Caimi, P. F. ; Cashen, A. ; Gallogly, M....
Hematological Oncology.  41 (2023)  S2 - p. 436-437 , 2023
Link: https://doi.org/10.1002/..
 
?
2

RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES ..:

Rebaud, L. ; Capobianco, N. ; Spottiswoode, B....
Hematological Oncology.  41 (2023)  S2 - p. 94-95 , 2023
Link: https://doi.org/10.1002/..
 
?
3

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WI..:

Sehn, L. H. ; Bartlett, N. L. ; Matasar, M....
Hematological Oncology.  41 (2023)  S2 - p. 122-125 , 2023
Link: https://doi.org/10.1002/..
 
?
4

GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:

Dickinson, M. ; Carlo‐Stella, C. ; Morschhauser, F....
Hematological Oncology.  41 (2023)  S2 - p. 144-146 , 2023
Link: https://doi.org/10.1002/..
 
?
5

Final Result of DIAL (NCI10089), Randomized Phase 2 trial o..:

Soekojo, C. Y. ; Yin, J. ; Kline, J....
Hematological Oncology.  41 (2023)  S2 - p. 592-594 , 2023
Link: https://doi.org/10.1002/..
 
?
6

COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE A..:

Hutchings, M. ; Dickinson, M. ; Carlo‐Stella, C....
Hematological Oncology.  41 (2023)  S2 - p. 136-138 , 2023
Link: https://doi.org/10.1002/..
 
?
7

Bacterial metabolites of dietary fibre fermentation, propio..:

Williams, L. ; Berthon, B. ; Bartlett, N...
Proceedings of the Nutrition Society.  82 (2023)  OCE2 - p. , 2023
Link: https://doi.org/10.1017/..
 
?
8

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazin..:

Abramson, J. S. ; Straus, D. ; Bartlett, N....
Hematological Oncology.  41 (2023)  S2 - p. 353-355 , 2023
Link: https://doi.org/10.1002/..
 
?
9

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARE..:

Herrera, A. F. ; LeBlanc, M. ; Castellino, S. M....
Hematological Oncology.  41 (2023)  S2 - p. 33-35 , 2023
Link: https://doi.org/10.1002/..
 
?
10

Multiphysics modeling and experimental validation of high-s..:

Rangapuram, M. ; Babalola, S. ; Newkirk, J. W....
Progress in Additive Manufacturing.  , 2023
Link: https://doi.org/10.1007/..
 
?
11

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY..:

Nastoupil, L. ; Morschhauser, F. ; Scholz, C. W....
HemaSphere.  6 (2022)  - p. 1015-1016 , 2022
Link: https://doi.org/10.1097/..
 
?
12

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB..:

Hutchings, M. ; Ansell, S. M. ; Straus, D. J....
HemaSphere.  6 (2022)  - p. 101-102 , 2022
Link: https://doi.org/10.1097/..
 
?
13

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology.  33 (2022)  3 - p. 288-298 , 2022
Link: https://doi.org/10.1016/..
 
?
14

P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN P..:

Matasar, M. ; Bartlett, N. L. ; Sehn, L. H....
HemaSphere.  6 (2022)  - p. 1016-1017 , 2022
Link: https://doi.org/10.1097/..
 
?
15

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE..:

Bartlett, N. L. ; Yasenchak, C. A. ; Ashraf, K. K....
HemaSphere.  6 (2022)  - p. 1064-1065 , 2022
Link: https://doi.org/10.1097/..
 
1-15